Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed Phase 2 Interventional

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 23, 2026, 2:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
CC-5013 (lenalidomide), dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258451
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328
View directory record Official record
Conditions
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions
Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities

NCT06532487
View directory record Official record
Conditions
Health Harming Legal Needs
Interventions
Critical Time Medical-Legal Partnership Intervention
Other
Lead sponsor
Stony Brook University
Other
Eligibility
13 Years and older
Enrollment
1,140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

NCT01119287
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

NCT05266417
View directory record Official record
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 3 Interventional Results available

Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

NCT00880191
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dexamethasone, gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
247
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 163 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Study of DA-9801 to Treat Diabetic Neuropathy

NCT01822925
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
DA-9801 300mg, DA-9801 600mg, DA-9801 900mg, Placebo
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Lakewood, California • Walnut Creek, California • Milford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 23, 2026, 2:06 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
YA-101, Placebo
Drug
Lead sponsor
Dasher Neuroscience Inc.
Industry
Eligibility
30 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Not applicable Interventional

C-SMART vs BE Well for Patients With Brain Tumors

NCT07224503
View directory record Official record
Conditions
Brain Tumor
Interventions
C-SMART, BE Well
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Active, not recruiting Not applicable Interventional

Auricular Acupuncture for Sleep Disturbances

NCT04956341
View directory record Official record
Conditions
Sleep Disturbance
Interventions
Auricular acupuncture, Standard treatment
Device · Other
Lead sponsor
Paul Crawford
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT00685386
View directory record Official record
Conditions
Cholestasis
Interventions
CO2 insufflation, Room air insufflation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 23, 2026, 2:06 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
TILD, matching placebo injections
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Covina, California • Miami Beach, Florida • New Port Richey, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Not applicable Interventional

REperfusion With Cooling in CerebraL Acute IscheMia II

NCT03804060
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Thermogard XP3, Recanalization only
Device · Procedure
Lead sponsor
ZOLL Circulation, Inc., USA
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Marietta, Georgia • Honolulu, Hawaii • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 23, 2026, 2:06 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Withdrawn Phase 2 Interventional

Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer

NCT01659424
View directory record Official record
Conditions
Rectal Cancer
Interventions
High Dose Rate Endorectal Brachytherapy (HDR-ERBT)
Radiation
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Not applicable Interventional

Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study

NCT03775759
View directory record Official record
Conditions
Tricuspid Valve Insufficiency, Right Heart Failure, Heart Failure
Interventions
Tricuspid valve repair or replacement, Medical management of tricuspid regurgitation
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 2:06 AM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 2:06 AM EDT
Completed Phase 2 Interventional

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

NCT00512083
View directory record Official record
Conditions
Leukemia, Myeloid
Interventions
AS1411
Drug
Lead sponsor
Antisoma Research
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • Beech Grove, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 23, 2026, 2:06 AM EDT